Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.
Gulam A. Manji, MD, PhD
Advertisement
Articles by Gulam A. Manji, MD, PhD
Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.
Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.
Gulam A. Manji, MD, PhD, discusses clinical trials for patients with colorectal cancer harboring BRAF or other molecular abnormalities.
Gulam A. Manji, MD, PhD, discusses the role of finding biomarkers in patients with gastrointestinal cancers.
Advertisement
Latest Updated Articles
Dr. Manji on Predictive or Prognostic Biomarkers in GI CancersPublished: July 15th 2019 | Updated:
- Dr. Manji on Treatment for BRAF-Mutant CRC
Published: August 16th 2019 | Updated:
- Dr. Manji on Treatment for Right-Sided Tumors in CRC
Published: September 4th 2019 | Updated:
Dr. Manji on Treatment for NTRK Fusion+ CRCPublished: September 18th 2019 | Updated:
Dr. Manji on Lack of Actionable Targets in Patients with Colorectal CancerPublished: October 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5